Terman D S, Durante D, Buffaloe G, McIntosh R
Scand J Immunol. 1977;6(3):195-202. doi: 10.1111/j.1365-3083.1977.tb00384.x.
A novel immunoadsorbent is described in which soluble canine glomerular basement membrane (GBM) antigen was immobilized in collodion membranes adherent to small charcoal particles. As much as 80% of the added GBM antigen was retained in the collodion-charcoal. The binding of GBM antibody to immobilized GBM antigen in vitro and in vivo was demonstrated. For in vivo studies, an extracorporeal circulation system was established, and mongrel dogs were then injected intravenously with GBM collodion-charcoal for 4 h. Renal tissue was examined by fluorescence and light microscopy for the deposition of heterologous gamma globulin and glomerular inflammation before and after the extracorporeal procedure. Results showed less deposition of heterologous IgG and less inflammation in experimental dog kidneys than in control kidneys. There was no evidence of release of 131I-labeled GBM from the immunoadsorbent at the conclusion of perfusion experiments and no significant biochemical or hematologic alterations. Finally, extracorporeal immunoadsorbent treatment was capable of attenuating the early heterologous phase of passive canine nephrotoxic nephritis and may have a potential role in the therapy of anti-GBM-mediated nephropathy.
描述了一种新型免疫吸附剂,其中可溶性犬肾小球基底膜(GBM)抗原固定在附着于小炭粒的火棉胶膜中。多达80%添加的GBM抗原保留在火棉胶 - 炭中。证明了GBM抗体在体外和体内与固定化GBM抗原的结合。对于体内研究,建立了体外循环系统,然后将杂种犬静脉注射GBM火棉胶 - 炭4小时。在体外操作前后,通过荧光和光学显微镜检查肾组织中异源γ球蛋白的沉积和肾小球炎症。结果显示,与对照肾脏相比,实验犬肾脏中异源IgG的沉积较少且炎症较轻。灌注实验结束时,没有证据表明131I标记的GBM从免疫吸附剂中释放,也没有明显的生化或血液学改变。最后,体外免疫吸附剂治疗能够减轻被动犬肾毒性肾炎的早期异源期,并且可能在抗GBM介导的肾病治疗中具有潜在作用。